Lech-Maranda E - Search Results

1

Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.

Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, Coiffier B, Salles G. Lech-Maranda E, et al. Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):131-41. doi: 10.1007/s00005-010-0066-1. Epub 2010 Feb 27. Arch Immunol Ther Exp (Warsz). 2010. PMID: 20191326 Free article.

2

The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro.

Lech-Maranda E, Korycka A, Robak T. Lech-Maranda E, et al. Haematologica. 2000 Jun;85(6):588-94. Haematologica. 2000. PMID: 10870114

3

Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.

Robak T, Wrzesień-Kuś A, Lech-Marańda E, Kowal M, Dmoszyńska A. Robak T, et al. Leuk Lymphoma. 2000 Sep;39(1-2):121-9. doi: 10.3109/10428190009053545. Leuk Lymphoma. 2000. PMID: 10975390

4

Influence of gemcitabine (2',2'-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro.

Lech-Marańda E, Korycka A, Robak T. Lech-Marańda E, et al. Eur J Haematol. 2000 Nov;65(5):317-21. doi: 10.1034/j.1600-0609.2000.065005317.x. Eur J Haematol. 2000. PMID: 11092462

5

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

Robak T, Góra-Tybor J, Lech-Marańda E, Błoński JZ, Kasznicki M. Robak T, et al. Eur J Haematol. 2001 Mar;66(3):188-94. doi: 10.1034/j.1600-0609.2001.00303.x. Eur J Haematol. 2001. PMID: 11350487 Clinical Trial.

6

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome.

Juszczynski P, Kalinka E, Bienvenu J, Woszczek G, Borowiec M, Robak T, Kowalski M, Lech-Maranda E, Baseggio L, Coiffier B, Salles G, Warzocha K. Juszczynski P, et al. Blood. 2002 Oct 15;100(8):3037-40. doi: 10.1182/blood-2002-02-0654. Blood. 2002. PMID: 12351419 Free article.

7

Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.

Wierzbowska A, Robak T, Wrzesień-Kuś A, Krawczyńska A, Lech-Marańda E, Urbańska-Ryś H. Wierzbowska A, et al. Eur Cytokine Netw. 2003 Jul-Sep;14(3):149-53. Eur Cytokine Netw. 2003. PMID: 14656688 Free article.

8

Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma.

Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B, Salles G. Lech-Maranda E, et al. Blood. 2004 May 1;103(9):3529-34. doi: 10.1182/blood-2003-06-1850. Epub 2003 Dec 30. Blood. 2004. PMID: 14701701 Free article.

9

Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma.

Lech-Maranda E, Bienvenu J, Michallet AS, Houot R, Robak T, Coiffier B, Salles G. Lech-Maranda E, et al. Eur Cytokine Netw. 2006 Mar;17(1):60-6. Eur Cytokine Netw. 2006. PMID: 16613764 Free article.

10

Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.

Robak T, Lech-Maranda E, Korycka A, Robak E. Robak T, et al. Curr Med Chem. 2006;13(26):3165-89. doi: 10.2174/092986706778742918. Curr Med Chem. 2006. PMID: 17168705

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters